ALNY (Alnylam Pharmaceuticals Inc.) stock: $239.56, $32.06B market cap, $3.31B cash, $28.75B EV, $36.55B fully diluted market cap. Next expected readout: Dec-26. Lead program: Nucresiran (Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy), Phase 3. Data from Fully Diluted's biotech stocks database.
Enterprise value
$28,747.2M
Balance sheet
| Cash | $3,308.1M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $3,308.1M |
|---|
| Enterprise value | $28,747.2M |
|---|
| Basic shares | 133.7M shares |
|---|
| Fully diluted shares | 152.6M shares |
|---|
| Fully diluted market cap | $36,552.1M |
|---|
| Cash per share | $24.74 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ALNY daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Feb 9 - Mar 23 | ALN-4285 | Phase 1 | Healthy Volunteers | — |
| Jun 8 - Jul 20 | ALN-2232 | Phase 2 | Obesity | — |
| Jul 9 - Aug 20 | ALN-4324 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | — |
| Aug 11 - Sep 22 | ALN-6400 | Phase 2 | Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB) | — |
| Sep 11 - Oct 23 | ALN-4915 | Phase 1 | Healthy Volunteers | — |
| Sep 20 - Nov 1 | ALN-APP | Phase 2 | Cerebral Amyloid Angiopathy | — |
| Oct 12 - Nov 23 | ALN-4324 | Phase 2 | Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM) | — |
| Nov 11 - Dec 23 | ALN-BCAT | Phase 1 | Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma | — |
| Jan 25 - Mar 7 | ALN-6222 | Phase 1 | Obesity | — |
| Feb 7 - Mar 20 | Nucresiran | Phase 3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN | — |
| Feb 16 - Mar 29 | ALN-6400 | Phase 2 | Hereditary Hemorrhagic Telangiectasia | — |
| May 12 - Jun 23 | Vutrisiran | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | — |
| May 13 - Jun 24 | ALN-AGT01 RVR | Phase 2 | Hypertension | — |
| Aug 16 - Sep 27 | ALN-HTT02 | Phase 1 | Huntington's Disease | — |
| Jun 1 - Jul 13 | ALN-APP | Phase 1 | Early-Onset Alzheimer Disease | — |
| Apr 17 - May 29 | ALN-5288 | Phase 1 | Alzheimer's Disease | — |
| Jun 29 - Aug 10 | Mivelsiran | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) | — |
| Jul 9 - Aug 20 | Nucresiran | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy | — |
| Nov 11 - Dec 23 | Zilebesiran | Phase 3 | High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
AMVUTTRA
Approved · Active Modality: siRNA
Aliases vutrisiran
Target TTR
Indications- ATTR amyloidosis with polyneuropathy (Approved)
- ATTR amyloidosis with cardiomyopathy (Approved)
Status note Subcutaneously administered RNAi therapeutic; company pursuing regulatory approval for cardiomyopathy indication in additional jurisdictions outside the US.
ONPATTRO
Approved · Active Modality: siRNA
Aliases patisiran
Target TTR
Indications- hATTR amyloidosis with polyneuropathy (Approved)
Status note Intravenously administered RNAi therapeutic.
GIVLAARI
Approved · Active Modality: siRNA
Aliases givosiran
Target ALAS1
Indications- acute hepatic porphyria (Approved)
OXLUMO
Approved · Active Modality: siRNA
Aliases lumasiran
Target HAO1
Indications- primary hyperoxaluria type 1 (Approved)
Leqvio
Approved · Active Modality: siRNA
Aliases inclisiran
Target PCSK9
Partnerships Novartis (commercialized by Novartis; ex-US rights via MDCO license)
Indications- hypercholesterolemia (Approved)
Status note July 2025 FDA label update enabled monotherapy use with diet and exercise to reduce LDL-C in adults with hypercholesterolemia.
Qfitlia
Approved · Active Modality: siRNA
Aliases fitusiran
Target AT (antithrombin)
Partnerships Sanofi (Genzyme; commercialized by Sanofi)
Indications- hemophilia A or B (Approved)
Status note FDA approved March 2025 for routine prophylaxis in patients 12+ with hemophilia A or B with or without inhibitors; NMPA approved December 2025.
zilebesiran
Phase 3 · Active Modality: siRNA
Target angiotensinogen (AGT)
Partnerships Roche (worldwide strategic collaboration for joint development; Alnylam received $675M license obligation transaction price)
Status note Investigational siRNA targeting liver-expressed angiotensinogen, in Phase 3 for hypertension.
mivelsiran
Stage not disclosed · Active Modality: siRNA
Aliases ALN-APP
Target amyloid precursor protein (APP)
Indications- cerebral amyloid angiopathy (CAA) (Stage not disclosed)
- Alzheimer's disease (Stage not disclosed)
Status note Intrathecally administered RNAi therapeutic; filing places it under early-stage clinical development programs; current phase not stated.
nucresiran
Phase 1 · Active Modality: siRNA
Target TTR
Indications- ATTR amyloidosis (Phase 1)
Status note Next-generation TTR silencer using IKARIA technology; positive interim Phase 1 results announced November 2024 (rapid TTR knockdown sustained six months after a single dose).
cemdisiran
Phase 3 · Active Modality: siRNA
Target C5
Partnerships Regeneron (solely responsible for development, manufacturing and commercialization; Alnylam receives milestones and tiered double-digit royalties)
Indications- paroxysmal nocturnal hemoglobinuria (PNH) (Phase 3)
- myasthenia gravis (Phase 3)
- geographic atrophy (Phase 3)
Status note Regeneron advancing cemdisiran in combination with its anti-C5 antibody pozelimab in Phase 3 for PNH, and as monotherapy and in combination with pozelimab in Phase 3 for myasthenia gravis and geographic atrophy.
Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.